Merck, Lundbeck end development of Phase III insomnia drug
Merck and Lundbeck have scrapped their joint-development program for insomnia treatment gaboxadol.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.